Fexofenadine/Pseudoephedrine tablets recalled for failed dissolution
Dr. Reddy's Laboratories is recalling Kroger Allergy Relief-D tablets (fexofenadine HCl 60mg/pseudoephedrine HCl 120mg) due to failed dissolution specifications. Approximately 11,064 boxes distributed nationwide are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class III recall. The source text identifies only a failed dissolution specification without reports of illness or injury. No clinical harm has been reported, making this a precautionary recall grounded in a manufacturing or quality-control issue rather than confirmed adverse events.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Kroger Allergy Relief-D Extended-Release Tablets, which contain fexofenadine HCl 60mg (antihistamine) and pseudoephedrine HCl 120mg (nasal decongestant), due to failed dissolution specifications. The affected product is NDC 30142-611-14, 20 tablets per box, manufactured in India and distributed by the Kroger Co.
Approximately 11,064 boxes with the following lot numbers have been distributed nationwide: AC2000968E (expiration 8/31/2022), AC2103328A (expiration 1/31/2023), AC2103330I (expiration 1/31/2023), and AC2106452B (expiration 3/31/2023).
Consumers who have purchased this product should stop using it and dispose of it safely. Persons with questions about this recall may contact Dr. Reddy's Laboratories or consult a healthcare provider.
The recalled product
- Product
- FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI (FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI)
- Brand
- FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Affected units
- 11,064
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #s: AC2000968E
- Exp. 8/31/2022
- AC2103328A
- AC2103330I
- Exp. 1/31/2023
- AC2106452B
- Exp. 3/31/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 9 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 9 products in this recall →Related recalls
Same brand · FEXOFENADINE HCL AND PSEUDOEPHEDRINE HCI
- LowWal-Fex D Allergy and Decongestant Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-01-26
- LowFexofenadine and Pseudoephedrine Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2021-12-15
- ModerateOTC Allergy and Congestion Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2021-12-15
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22